| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old (NCT07536269) | Neurocrine Biosciences | 2026-04-01 |
| Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia (NCT07288333) | Neurocrine Biosciences | 2026-02-16 |
| Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia (NCT07365462) | Neurocrine Biosciences | 2026-02-06 |
| An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania (NCT07288320) | Neurocrine Biosciences | 2025-12-24 |
| Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia (NCT07227818) | Neurocrine Biosciences | 2025-12-16 |
| Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old (NCT07187375) | Neurocrine Biosciences | 2025-09-30 |
| A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor (NCT07105111) | Neurocrine Biosciences | 2025-08-29 |
| A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) (NCT07196501) | Neurocrine Biosciences | 2025-08-18 |
| NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia (NCT07105098) | Neurocrine Biosciences | 2025-08-11 |
| NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia (NCT07114874) | Neurocrine Biosciences | 2025-07-11 |
| NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) (NCT06963021) | Neurocrine Biosciences | 2025-05-30 |
| NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia (NCT06963034) | Neurocrine Biosciences | 2025-05-08 |
| Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) (NCT06966401) | Neurocrine Biosciences | 2025-04-16 |
| NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) (NCT06911112) | Neurocrine Biosciences | 2025-03-31 |
| Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) (NCT06786624) | Neurocrine Biosciences | 2025-01-22 |
| Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada (NCT06312189) | Neurocrine Biosciences | 2024-04-24 |
| A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder (NCT06267846) | Neurocrine Biosciences | 2024-03-20 |
| Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia (NCT05859698) | Neurocrine Biosciences | 2023-05-09 |
| Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia (NCT05654870) | Neurocrine Biosciences | 2023-01-05 |
| Extension Study to Evaluate the Safety and Tolerability of NBI-921352 When Used With Anti-seizure Medications in Adults With Focal Onset Seizures (NCT05493293) | Neurocrine Biosciences | 2022-11-09 |
| Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With Schizophrenia (NCT05545111) | Neurocrine Biosciences | 2022-10-04 |
| Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEE (NCT05226780) | Neurocrine Biosciences | 2022-07-12 |
| Extension Study to Evaluate NBI-827104 in Pediatric Participants With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep (NCT05301894) | Neurocrine Biosciences | 2022-06-07 |
| Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy (NCT05206513) | Neurocrine Biosciences | 2022-04-15 |
| Study to Assess the Efficacy and Safety of NBI-1065845 in Adults With Major Depressive Disorder (MDD) (NCT05203341) | Neurocrine Biosciences | 2022-02-21 |
| Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE) (NCT04873869) | Neurocrine Biosciences | 2022-01-31 |
| Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With Schizophrenia (NCT05182476) | Neurocrine Biosciences | 2021-12-07 |
| Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD (NCT05165394) | Neurocrine Biosciences | 2021-11-30 |
| Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia (NCT05110157) | Neurocrine Biosciences | 2021-11-29 |
| A Study to Investigate How Effective, Safe and Tolerable the Drug NBI-921352 is When Used With Anti-seizure Medications in Adults With Focal Onset Seizures (NCT05159908) | Neurocrine Biosciences | 2021-11-08 |
| Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study) (NCT04806451) | Neurocrine Biosciences | 2021-06-25 |
| Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric Subjects With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep (NCT04625101) | Neurocrine Biosciences | 2021-04-26 |
| Safety, Efficacy, and Tolerability of NBI-827104 for the Treatment of Essential Tremor (NCT04880616) | Neurocrine Biosciences | 2021-04-20 |
| Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease (NCT04400331) | Neurocrine Biosciences | 2020-09-18 |
| A Study to Assess Absolute Bioavailability (ABA) of TAK-831 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]TAK-831 in Male Healthy Participants (NCT04234672) | Neurocrine Biosciences | 2020-02-17 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 (Crinecerfont) in Pediatric Participants With Congenital Adrenal Hyperplasia (NCT04045145) | Neurocrine Biosciences | 2019-12-12 |
| Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease (NCT04102579) | Neurocrine Biosciences | 2019-11-13 |
| Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia (NCT03891862) | Neurocrine Biosciences | 2019-03-18 |
| A Study to Evaluate Central Nervous System (CNS) Pharmacodynamic Activity of TAK-653 in Healthy Participants Using Transcranial Magnetic Stimulation (TMS) (NCT03792672) | Neurocrine Biosciences | 2019-02-11 |
| A Study to Evaluate the Relative Bioavailability (BA) and Effect of Food on TAK-831 Tablet Formulations in Healthy Participants (NCT03706469) | Neurocrine Biosciences | 2018-10-18 |
| Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome (NCT03732534) | Neurocrine Biosciences | 2018-10-17 |
| VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1) (NCT03562494) | Neurocrine Biosciences | 2018-10-17 |
| Phase 1 Study of TAK-831 in Healthy Adult Asian Subjects (NCT03687684) | Neurocrine Biosciences | 2018-10-09 |
| The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine (NCT03698331) | Neurocrine Biosciences | 2018-09-14 |
| Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome (NCT03530293) | Neurocrine Biosciences | 2018-04-17 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Adults With Congenital Adrenal Hyperplasia (NCT03525886) | Neurocrine Biosciences | 2018-04-10 |
| Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome (NCT03444038) | Neurocrine Biosciences | 2018-02-08 |
| A Study to Evaluate Multiple Oral Doses of Luvadaxistat in Adults With Schizophrenia (NCT03359785) | Neurocrine Biosciences | 2018-01-10 |
| A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia (NCT03319953) | Neurocrine Biosciences | 2017-12-21 |
| Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia (NCT03214588) | Neurocrine Biosciences | 2017-11-08 |
| Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome (NCT03325010) | Neurocrine Biosciences | 2017-10-05 |